Company Overview
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $189.76M (+45.8% YoY); net profit $-196.54M.
- Trailing 12 Months Year-on-year growth — revenue +83.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 83.80% |
Stock Price Performance
| 1 Year: | +23.34% |
| 6 Months: | +8.85% |
| 3 Months: | +26.67% |
| 1 Month: | +25.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RYTM Rhythm Pharmaceuticals, Inc. R2K | 109.96 | -35.13 | $7.54B | 0.00% | -51.31% | -101.16% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.50M | 25.97M | 29.08M | 33.25M | 32.70M | 48.50M | 51.30M | 60.11M |
| Operating Income | -6.40M | -6.39M | -6.75M | -8.29M | -17.00M | -15.02M | -19.24M | - | -30.52M | -44.15M | -37.11M | - | -35.30M | -31.92M | -34.28M | -34.40M | -40.43M | -44.24M | -52.69M | -45.10M | -39.27M | -52.53M | -46.60M | -43.95M | -139.89M | -40.48M | -43.88M | -47.00M | -45.30M | -52.65M | -52.36M |
| Net Income | - | - | - | - | -16.46M | -14.41M | -17.69M | -25.51M | -28.97M | -42.80M | -36.00M | -32.96M | -34.16M | -31.12M | -33.82M | 43.75M | -35.39M | -35.11M | -52.76M | -45.00M | -40.86M | -52.18M | -46.70M | -44.16M | -141.37M | -32.26M | -43.64M | -49.50M | -46.63M | -52.90M | -55.64M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.78 | -0.71 | - | 0.90 | -0.70 | -0.70 | -1.05 | -0.89 | -0.79 | -0.92 | -0.82 | -0.76 | -2.35 | -0.55 | -0.73 | -0.81 | -0.75 | -0.82 | -0.83 |
| R&D Expense | 5.42M | 4.87M | 5.40M | 5.97M | 12.29M | 8.58M | 10.71M | - | 22.76M | 35.31M | 26.57M | - | 22.50M | 23.00M | 23.00M | 19.91M | 25.10M | 27.54M | 32.51M | 31.46M | 21.12M | 37.95M | 33.54M | 33.57M | 128.66M | 30.19M | 37.93M | 36.97M | 42.31M | 46.03M | 41.73M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 | 3.15M | 23.64M | 77.43M | 130.13M | 189.76M |
| Operating Income | -10.57M | -25.91M | -32.41M | -78.42M | -146.00M | -136.57M | -170.06M | -179.16M | -184.36M | -265.50M | -192.02M |
| Net Income | -12.00M | -29.07M | -33.71M | -74.06M | -140.73M | -134.00M | -69.61M | -181.12M | -184.68M | -260.60M | -196.54M |
| Diluted EPS | - | - | - | - | -3.86 | -3.04 | -1.40 | -3.47 | -3.20 | -4.34 | -3.11 |
| R&D Expense | 7.15M | 19.59M | 22.89M | 50.34M | 109.45M | 90.45M | 104.13M | 108.63M | 134.95M | 237.96M | 167.34M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.34M | 151.74M | 260.21M | 308.52M | 187.07M | 329.52M | 382.48M | 332.75M | 392.27M | 480.20M |
| Total Equity | -358.00K | -8.00M | -32.70M | 144.79M | 246.26M | 281.02M | 166.53M | 284.15M | 264.26M | 169.76M | 21.73M | 139.07M |
| Cash & Equivalents | 152.00K | 34.87M | 6.54M | 34.24M | 49.54M | 62.29M | 100.85M | 59.25M | 127.68M | 60.08M | 89.14M | 54.30M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 106.14M | 108.27M | 100.89M |
| Total Liabilities | - | - | 5.04M | 6.95M | 13.95M | 27.50M | 20.55M | 45.37M | 118.22M | 162.99M | 227.72M | 210.17M |
| Current Liabilities | - | - | 4.73M | 6.72M | 13.58M | 24.42M | 17.99M | 43.43M | 39.81M | 55.20M | 115.52M | 105.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.98M | -23.22M | -29.46M | -62.06M | -122.75M | -121.98M | -146.00M | -173.43M | -136.16M | -113.88M | -115.67M |
| Investing Cash Flow | -17.00K | -5.11M | -110.04M | -87.15M | -27.97M | 158.53M | -62.16M | 28.03M | -5.67M | -48.17M | -137.15M |
| Financing Cash Flow | 41.71M | - | 167.20M | 164.69M | 163.47M | 2.01M | 166.48M | 213.83M | 74.37M | 191.24M | 217.96M |
| Capital Expenditure | -17.00K | -1.06M | -133.00K | -722.00K | -3.38M | -214.00K | -434.00K | -281.00K | -47.00K | -0 | -953.00K |
| Free Cash Flow | -6.99M | -24.28M | -29.59M | -62.78M | -126.14M | -122.19M | -146.44M | -173.71M | -136.20M | -113.88M | -116.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -5,391.9% | -757.9% | -238.1% | -204.0% | -101.2% |
| Net Margin % | - | - | - | - | - | - | -2,207.1% | -766.2% | -238.5% | -200.3% | -103.6% |
| ROE % | 150.0% | 88.9% | -23.3% | -30.1% | -50.1% | -80.5% | -24.5% | -68.5% | -108.8% | -1,199.3% | -141.3% |
| ROCE % | - | -340.5% | -22.4% | -31.8% | -51.4% | -80.8% | -59.4% | -52.3% | -66.4% | -95.9% | -51.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.73% | 6.67M | $744.75M |
| 2 | Blackrock Inc. | 9.10% | 6.24M | $696.75M |
| 3 | Baker Bros. Advisors, LP | 8.18% | 5.60M | $626.08M |
| 4 | Primecap Management Company | 4.99% | 3.42M | $381.77M |
| 5 | Vanguard Portfolio Management LLC | 4.44% | 3.04M | $339.68M |
| 6 | Vanguard Capital Management LLC | 4.33% | 2.97M | $331.54M |
| 7 | Perceptive Advisors Llc | 3.46% | 2.37M | $265.18M |
| 8 | State Street Corporation | 3.31% | 2.27M | $253.79M |
| 9 | Goldman Sachs Group Inc | 2.87% | 1.97M | $219.56M |
| 10 | Westfield Capital Management Co LP | 2.81% | 1.93M | $215.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RYTM
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNanBLVzRFMXE1Q0NocTNSZllJRHBGdVBkalBIc3J3OTBzWVhHd25aWFVvb2d6a1c5Ykc5bDJra1dBNW5pZUhHNEgtY1hpZFJ1a2trWTJ5NnRFcl9QdEpCbFJZOTlqclA5UlItcndiUWhrZGxvLTgxakdvcElmeGJVMmN4N0twU0F5YmVKTm…
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQaE9tRlhuVGRxVlhrSEJQZVZEUU5Dd185NktuOFZhWmktMDAydEFSMklqc3pjUjdDMkgxRVlKM0lZZVhpdkZTd2owVWNzeEdhUl9tMXI5bVIxUlk0c08xQ2tjMGdlejMxTjlSYjV3V2Y2cUc3dFJob3Rwc2NpQ1NsclB1UFFkeWVldXlCZU…
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQd1lzUlpadlphSGZIRjlaRG9XZUR2SFhJSEE2cGhjRnppekRMZ3FBYjRVWTI2UTZkOGJRV3VCNmdHb3lHZXc5VFhRVWwzRTBlcWxoa1pnQWNtdkpySFNpZGxBV2pjUTJuUWl1RGhwTk1BNFhYWk1lcnIzdkdrSWlGOFNOczd3VEFkM0hVRX…
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPOGxwUHZCZzk3NXFqd1lNdnNJS002VjlWb1dfVkFKUExHTW1LTW5xYWw3akxNVHNwVkk5Z2M1M2phYkRONnNDT0ZtLWV6SHQtbHRvTXdjVTRVei1tOVNtQTdUQmlHT3NYNDUyOGRKV0QxTWNJbGlLd1VGQ19DQlE3SGY5R2NCRmpObGhrM2…
Rhythm’s obesity drug data lands in NEJM after 52-week Phase 3 trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRy1vemRhWDhLYm9VbkU3M1BGcEpXY1l0bWduTzI1d2w5MzhldzQ0ZVZaYjJyU2hVMm9Ld2hxVWdlNmtVYTJTLXhMbHgwdU1WMTNPY3ZpMHI2bDlrSmNKTUJXMFR3LWVzV3lWU1hEc0V3ZnV6eUQwOFkyb3VNYlBTLVBEaVU4cUsteHJIY3…
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQYWRUOTM5dHBpSEcwLXQzV1pwQUtIblczTS03Y3NONTFPOTVIYnJ5a3RBT0JmRmpQS2NfVGpBNlFGRTVDZU1sdl82VTZSc2JNYnlYN0NObjlGd1RwUHFHSXNJajdUaExjRXFROHdLLWxTWmZ1NUVZSVFRM3NGTWlnV3hjV2RkT25zamJoTX…
RYTM — Frequently Asked Questions
What is the current share price of Rhythm Pharmaceuticals, Inc. (RYTM)?
As of 2026-07-14 21:23 PDT, Rhythm Pharmaceuticals, Inc. (RYTM) trades at $109.96 on NasdaqGM. Its 52-week range is $75.82 to $117.62.
What is the market capitalisation of RYTM?
Rhythm Pharmaceuticals, Inc. (RYTM) has a market capitalisation of $7.54B on NasdaqGM.
What is the P/E ratio of RYTM?
RYTM trades at a trailing price-to-earnings (P/E) ratio of -35.13. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 49.21.
What is the return on equity (ROE) of RYTM?
RYTM has a return on equity (ROE) of -101.16%. Its return on capital employed (ROCE) is -51.31%.
Is RYTM a good stock to buy?
This page provides a data-driven analysis of Rhythm Pharmaceuticals, Inc. (RYTM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.